VENTANA PD-L1(SP263) Assay Testing Centers

VENTANA PD-L1(SP263) Assay

The only FDA approved test to predict a urothelial carcinoma patient’s response to IMFINZI™* (durvalumab)

Using an approved assay to determine PD-L1 status for immunotherapy options is important. VENTANA PD-L1 (SP263) Assay equips pathologists by

  • Identifying urothelial carcinoma patients most likely to benefit from IMFINZI™ (durvalumab)
  • Providing robust PD-L1 staining in both tumor cells (TC) and tumor-infiltrating immune cells (IC)

* IMFINZI™ (durvalumab) is a trademark of AstraZeneca Pharmaceutical Company. All rights reserved.

Test Centers

NeoGenomics Laboratories

31 Columbia
Aliso Viejo, CA 92656
Phone: 866-776-5907
www.neogenomics.com

Aurora Diagnostics LMC Pathology Services

7455 W. Washington Avenue, Suite 301
Las Vegas, NV 89128
Phone: 877-LMC-LABS
Phone: 702-732-3441
Fax: 702-732-2310
www.auroradxlmc.com

Acupath Labs, Inc.

28 South Terminal Drive
Plainview, NY 11803
Phone: 1-888-ACUPATH
Fax: 1-516-576-8408
www.acupath.com

Cancer Genetics Inc.

201 New Jersey 17
Rutherford, NJ 07070
Phone: 201-528-9200
www.cancergenetics.com

Providence Portland Medical Center

4805 NE Glisan St
Portland, OR 97213
Phone: 503-893-7777
www.providence.org

Celligent Diagnostics

101 E WT Harris Suite 1212
Charlotte, NC 28262
Phone: 704-549-8444
Fax: 704-549-0559
www.celligent.net

If you would like your lab featured on this list, please opt in here.